Bijal D. Shah, MD
Therapeutic approaches, including chimeric antigen receptor (CAR) T-cell therapy, are being explored in patients with mantle cell lymphoma (MCL) who have demonstrated resistance to the BTK inhibitor ibrutinib (Imbruvica)—a patient population that is worrisome to practitioners, explains Bijal D. Shah, MD.
State of the Science Summit on Hematologic Malignancies.
OncLive®: What is generating excitement in the field of MCL?
When I think about MCL, the most complicated patient I see now is the ibrutinib-resistant patient, particularly those who develop ibrutinib resistance early. These individuals tend to have extraordinarily aggressive lymphoma, and these lymphomas tend to be very chemotherapy resistant. I’m going to cite data from Moffitt Cancer Center. For our patients, the median survival when someone progresses on ibrutinib is only about 2 months. About three-fourths of the group who die within 2 months, die within the first 2 or 3 weeks, just to give some insight of what we’re running up against.
... to read the full story